Streetbeat News

Analyst Ratings

NVRO

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Nevro (NYSE:NVRO) and lowers the price target from $6.89 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:28 pm

ENOV

Evercore ISI Group has maintained an 'Outperform' rating on Enovis (NYSE:ENOV) but has lowered the price target from $62 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:28 pm

MDT

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Medtronic (NYSE:MDT) but raises the price target from $85 to $92.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:27 pm

NFLX

Netflix is expected to see a boost in its stock valuation due to upcoming content releases, including two NFL games and 'Squid Game' Season 2. Analyst Justin Patterson from KeyBanc Capital Markets has raised the price target for Netflix, citing strong content catalysts in Q4 and potential EPS growth in 2025 and 2026.

Portfolio Pulse from Chris Katje

October 01, 2024 | 4:25 pm

IART

Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:25 pm

DHR

Evercore ISI Group has maintained an 'Outperform' rating on Danaher (NYSE:DHR) and raised its price target from $275 to $278.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:24 pm

ITGR

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Integer Holdings (NYSE:ITGR) and raises the price target from $124 to $130.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:23 pm

PODD

Citigroup analyst Joanne Wuensch maintains a Buy rating on Insulet (NASDAQ:PODD) and raises the price target from $250 to $275.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:21 pm

ESTA

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Establishment Labs Holdings (NASDAQ:ESTA) and raises the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:20 pm

EW

Citigroup analyst Joanne Wuensch maintains a Buy rating on Edwards Lifesciences but lowers the price target from $83 to $77.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:18 pm